Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes (MDS): Are They Two Faces of the Same Coin? a Study on Behalf of the MDS Clinical Research Consortium (MDS CRC)

Rami S. Komrokji, MD, John Barnard, PhD, David P Steensma, MD, Amy E. DeZern, MD MHS, Gail J. Roboz, Najla Alali, MS, Jaime Fensterl, Guillermo Garcia-Manero, MD, Mikkael A. Sekeres, MD MS

Blood (2016) 128 (22): 4321.

https://doi.org/10.1182/blood.V128.22.4321.4321

Published: 2016

Journal Articles

Optimal Treatment Order of Lenalidomide and Hypomethylating Agents for Lower-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium

Rami S. Komrokji, MD, Mikkael A. Sekeres, MD MS, John Barnard, PhD, Najla Alali, MS, Amy E. DeZern, MD MHS, Eric Padron, MD, David Sallman, MD, Jeffrey E. Lancet, MD, Gail J. Roboz, Jaime Fensterl, Guillermo Garcia-Manero, MD, David P. Steensma, MD, Alan F List, MD

Blood (2016) 128 (22): 4322.

https://doi.org/10.1182/blood.V128.22.4322.4322

Published: 2016

Journal Articles

Is Serial Monitoring of Myeloid Mutations Clinically Relevant in Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC)

Sangmin Lee, MD, John Barnard, PhD, Amy E. DeZern, MD MHS, Jaroslaw P Maciejewski, MD PhD FACP, Najla Alali, MS, David P. Steensma, MD, Ellen K. Ritchie, MD, Pinkal Desai, MD, Guillermo Garcia-Manero, MD, Fatima Ali, B.S., Nicole Rizzo, BA, Duane C Hassane, PhD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD MS, Gail J. Roboz

Blood (2016) 128 (22): 297.

https://doi.org/10.1182/blood.V128.22.297.297

Published: 2016

Journal Articles

EZH2 Protein Expression Is Decreased in MDS and MDS/MPN and Correlated with EZH2 Mutation Status, Chromosomal 7 Abnormalities and Clinical Outcome

Kathy L Mcgraw, PhD, Johnny Nguyen, Najla Alali, MS, Jinming Song, MD PhD, David Sallman, MD, Eric Padron, MD, Jeffrey E. Lancet, MD, Daihui Qin, P.K. Epling-Burnette, PhD, Lynn C. Moscinski, MD, Rami S. Komrokji, MD, Alan F List, MD, Ling Zhang, MD

Blood (2016) 128 (22): 4305.

https://doi.org/10.1182/blood.V128.22.4305.4305

Published: 2016

Journal Articles

Myelodysplastic/Myeloproliferative Neoplasms Unclassified (MDS/MPN-U) Overlap: Can We Alter the Natural History?

Kaitlin Hendrix, NP, MSN, Najla Alali, MS, Eric Padron, MD, David Sallman, MD, Alan F. List, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD

Blood (2016) 128 (22): 3125.

https://doi.org/10.1182/blood.V128.22.3125.3125

Published: 2016

Journal Articles

Characterization of Myelodysplastic Syndromes (MDS) with T-Cell Large Granular Lymphocyte Proliferations (LGL)

Christa Roe, MA, BS, RN, OCN, Najla Alali, MS, Eric Padron, MD, Pearlie K Burnette, PhD, Kendra L. Sweet, MD, David Sallman, MD, Lubomir Sokol, MD PhD, Jeffrey E. Lancet, MD, Alan F. List, MD, Rami S Komrokji, MD

Blood (2016) 128 (22): 113.

https://doi.org/10.1182/blood.V128.22.113.113

Published: 2016

NARROW

Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes (MDS): Are They Two Faces of the Same Coin? a Study on Behalf of the MDS Clinical Research Consortium (MDS CRC)

Optimal Treatment Order of Lenalidomide and Hypomethylating Agents for Lower-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium

Is Serial Monitoring of Myeloid Mutations Clinically Relevant in Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC)

EZH2 Protein Expression Is Decreased in MDS and MDS/MPN and Correlated with EZH2 Mutation Status, Chromosomal 7 Abnormalities and Clinical Outcome

Myelodysplastic/Myeloproliferative Neoplasms Unclassified (MDS/MPN-U) Overlap: Can We Alter the Natural History?

Characterization of Myelodysplastic Syndromes (MDS) with T-Cell Large Granular Lymphocyte Proliferations (LGL)

Email alerts

ASH Publications

American Society of Hematology

Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes (MDS): Are They Two Faces of the Same Coin? a Study on Behalf of the MDS Clinical Research Consortium (MDS CRC)

Optimal Treatment Order of Lenalidomide and Hypomethylating Agents for Lower-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium

Is Serial Monitoring of Myeloid Mutations Clinically Relevant in Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC)

EZH2 Protein Expression Is Decreased in MDS and MDS/MPN and Correlated with EZH2 Mutation Status, Chromosomal 7 Abnormalities and Clinical Outcome

Myelodysplastic/Myeloproliferative Neoplasms Unclassified (MDS/MPN-U) Overlap: Can We Alter the Natural History?

Characterization of Myelodysplastic Syndromes (MDS) with T-Cell Large Granular Lymphocyte Proliferations (LGL)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only